Therapeutic targeting of platelet-derived growth factor receptors in solid tumors

Expert Opinion on Investigational Drugs

Volumn 23, Issue 2, 2014, Pages 211-226

  Ehnman, Monika ^a   Östman, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Cancer; Clinical trials; Platelet derived growth factor; Stroma; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CRENOLANIB; DASATINIB; DOVITINIB; HYDROXYUREA; IMATINIB; LENVATINIB; LINIFANIB; MASITINIB; MONOCLONAL ANTIBODY; MOTESANIB; NILOTINIB; NINTEDANIB; ORANTINIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SILDENAFIL; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CHILDHOOD CANCER; CHORDOMA; CLINICAL TRIAL (TOPIC); DERMATOFIBROSARCOMA PROTUBERANS; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; FIBROBLAST; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 84892378119     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.847086     Document Type: Review

References (112)

1. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
2. Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012;148(6):1089-98
3. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011;81(10):1183-91
4. McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013;12(3):217-28
5. Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012;18(9):1332-4
6. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22(10):1276-312 (Pubitemid 351717519)
7. Siegfried G, Basak A, Prichett-Pejic W, et al. Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene 2005;24(46):6925-35 (Pubitemid 41509415)
8. Siegfried G, Khatib AM, Benjannet S, et al. The proteolytic processing of pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 2003;63(7):1458-63 (Pubitemid 36373629)
9. Ehnman M, Li H, Fredriksson L, et al. The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth. Oncogene 2009;28(4):534-44
10. Fredriksson L, Ehnman M, Fieber C, et al. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem 2005;280(29):26856-62 (Pubitemid 41040719)
11. Ustach CV, Kim HR. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 2005;25(14):6279-88 (Pubitemid 40946575)
12. Fredriksson L, Li H, Fieber C, et al. Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J 2004;23(19):3793-802 (Pubitemid 39389710)
13. Ustach CV, Huang W, Conley-LaComb MK, et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 2010;70(23):9631-40
14. Ronnstrand L. Signaling by the platelet-derived growth factor receptor family. In: Bradshaw RA, Dennis EA, editors. Handbook of cell signaling. 2nd edition. Elsevier/Academic Press; 2010. p. 427-34
15. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004;15(4):215-28 (Pubitemid 38781047)
16. Morrison-Graham K, Schatteman GC, Bork T, et al. A PDGF receptor mutation in the mouse (Patch) perturbs the development of a non-neuronal subset of neural crest-derived cells. Development 1992;115(1):133-42
17. Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999;126(14):3047-55 (Pubitemid 29378170)
18. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15(4):275-86 (Pubitemid 38781051)
19. Nazarenko I, Hede SM, He X, et al. PDGF and PDGF receptors in glioma. Ups J Med Sci 2012;117(2):99-112
20. Ehnman M, Missiaglia E, Folestad E, et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 2013;73(7):2139-49
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70
23. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004;61(23):2912-23 (Pubitemid 40104589)
24. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15(11):1311-33 (Pubitemid 32524640)
25. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
26. Joensuu H, Puputti M, Sihto H, et al. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005;207(2):224-31 (Pubitemid 41404153)
27. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
28. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28(18):3061-8
29. Paugh BS, Zhu X, Qu C, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res 2013. [Epub ahead of print]
30. Puget S, Philippe C, Bax DA, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 2012;7(2):e30313
31. Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 2010;96(3):393-402
32. Paulsson J, Lindh MB, Jarvius M, et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 2011;128(8):1981-8
33. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;15(1):95-8 (Pubitemid 27014958)
34. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999;59(15):3719-23 (Pubitemid 29381878)
35. Kikuchi K, Soma Y, Fujimoto M, et al. Dermatofibrosarcoma protuberans: increased growth response to platelet-derived growth factor BB in cell culture. Biochem Biophys Res Commun 1993;196(1):409-15 (Pubitemid 23309523)
36. Greco A, Roccato E, Miranda C, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001;92(3):354-60 (Pubitemid 32249711)
37. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61(15):5778-83 (Pubitemid 32769094)
38. Malhotra B, Schuetze SM. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Curr Opin Oncol 2012;24(4):419-24
39. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23(4):866-73 (Pubitemid 46224187)
40. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21(23):4342-9 (Pubitemid 46621810)
41. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708-10 (Pubitemid 36159485)
42. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26(33):5360-7
43. Wardelmann E, Neidt I, Bierhoff E, et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002;15(2):125-36 (Pubitemid 34171322)
44. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28(7):889-94 (Pubitemid 38856844)
45. Wozniak A, Rutkowski P, Piskorz A, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012;23(2):353-60
46. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004;84(7):874-83 (Pubitemid 38833247)
47. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125(3):660-7 (Pubitemid 37070684)
48. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40(5):689-95 (Pubitemid 38326618)
49. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620-5 (Pubitemid 351264357)
50. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23(23):5357-64 (Pubitemid 46206989)
51. Joensuu H. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. Drugs 2012;72(15):1953-63
52. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307(12):1265-72
53. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009;27(19):3148-53
54. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86
55. Song S, Ewald AJ, Stallcup W, et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7(9):870-9 (Pubitemid 41486287)
56. Rolny C, Nilsson I, Magnusson P, et al. Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation. Blood 2006;108(6):1877-86 (Pubitemid 44394997)
57. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6(4):333-45 (Pubitemid 39361435)
58. Xue Y, Lim S, Yang Y, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012;18(1):100-10
59. Hosaka K, Yang Y, Seki T, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun 2013;4:2129
60. Furuhashi M, Sjoblom T, Abramsson A, et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004;64(8):2725-33 (Pubitemid 38500608)
61. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21(1):66-81
62. Augsten M, Hagglof C, Pena C, et al. A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron 2010;3(1):167-76
63. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta 2013;1832(7):1070-8
64. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196(4):395-406
65. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139(5):891-906
66. Strell C, Rundqvist H, Ostman A. Fibroblasts-a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci 2012;117(2):187-95
67. Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012;151(7):1542-56
68. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449(7162):557-63 (Pubitemid 47525152)
69. Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22(5):571-84
70. Jedeszko C, Victor BC, Podgorski I, et al. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res 2009;69(23):9148-55
71. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487(7408):505-9
72. Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012;18(9):1359-68
73. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487(7408):500-4
74. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4(10):806-13 (Pubitemid 39331152)
75. Pena C, Cespedes MV, Lindh MB, et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013;73(4):1287-97
76. Hagglof C, Hammarsten P, Josefsson A, et al. Stromal PDGFR beta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One 2010;5(5):e10747
77. Paulsson J, Sjoblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009;175(1):334-41
78. Frings O, Augsten M, Tobin NP, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am J Pathol 2013;182(6):2037-47
79. van Zijl F, Mair M, Csiszar A, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009;28(45):4022-33
80. Rosenberg A, Mathew P. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013;22(6):787-94
81. Conley-LaComb MK, Huang W, Wang S, et al. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 2012;180(3):1017-27
82. Najy AJ, Jung YS, Won JJ, et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 2012;72(12):1328-38
83. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62(19):5476-84
84. Falcon BL, Pietras K, Chou J, et al. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 2011;178(6):2920-30
85. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61(7):2929-34 (Pubitemid 32691937)
86. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9(10 Pt 1):3779-87 (Pubitemid 37169248)
87. Grassot J, Gouy M, Perriere G, et al. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Mol Biol Evol 2006;23(6):1232-41 (Pubitemid 43781597)
88. Broniscer A, Baker SD, Wetmore C, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 2013;19(11):3050-8
89. Lewis NL, Lewis LD, Eder JP, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009;27(31):5262-9
90. Le Cesne A, Blay JY, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010;46(8):1344-51
91. Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14(18):5749-58
92. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012;18(16):4375-84
93. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012;30(9):914-20
94. Sugiura H, Fujiwara Y, Ando M, et al. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 2010;15(5):654-60
95. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005;23(5):982-9 (Pubitemid 46202318)
96. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24(7):1195-203 (Pubitemid 46638818)
97. Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010;16(19):4884-91
98. Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005;4(3):369-79 (Pubitemid 40443922)
99. Gerber DE, Gupta P, Dellinger MT, et al. Stromal platelet-derived growth factor receptor alpha (PDGFRalpha) provides a therapeutic target independent of tumor cell PDGFRalpha expression in lung cancer xenografts. Mol Cancer Ther 2012;11(11):2473-82
100. Laing N, McDermott B, Wen S, et al. Inhibition of PDGFRalpha by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol 2013;83(6):1247-56
101. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 2010;16(20):5002-10
102. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008;14(7):731-7
103. Adzemovic MZ, Zeitelhofer M, Eriksson U, et al. Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One 2013;8(2):e56586
104. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):973-7
105. Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012;149(2):307-21
106. Akhavan D, Pourzia AL, Nourian AA, et al. De-Repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013;3(5):534-47
107. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 2012;7(2):e26331
108. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31(17):2205-18
109. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30(21):2601-8
110. Jarvius M, Paulsson J, Weibrecht I, et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007;6(9):1500-9 (Pubitemid 47506163)
111. Koos B, Paulsson J, Jarvius M, et al. Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am J Pathol 2009;175(4):1631-7
112. Lindborg M, Cortez E, Hoiden-Guthenberg I, et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 2011;407(2):298-315